Trillium Therapeutics Inc. – NASDAQ:TRIL

Add to watchlist

$18.44

Market closed

Open in 1 day

+3.42%

quarter

+29.68%

year

Market Cap	N/A
Enterprise value	1.84B

P/E	29.70
EV/Sales	42812.99
EV/EBITDA	28.12
Price/Sales	44965.85
Price/Book	7.95
PEG ratio	0.51
EPS	0.89

Revenue	N/A
EBITDA	65.46M
Income	65.08M
Revenue Q/Q	N/A
Revenue Y/Y	-82.00%

Profit margin	151351.16%
Oper. margin	-161183.72%
Gross margin	76.74%
EBIT margin	-161183.72%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Trillium Therapeutics Inc. (NASDAQ:TRIL): Profit margin
Dec 2020	33K	113.65M	344418.18%
Mar 2021	0	-10.86M
Jun 2021	10K	-18.39M	-183990%
Sep 2021	0	-19.31M

Trillium Therapeutics Inc. (NASDAQ:TRIL): Earnings per share (EPS)
2020-08-12	-0.13	-0.63
2021-05-07	-0.18	-0.11
2021-08-13	-0.16	-0.18
2021-11-12	-0.25	-0.23

Trillium Therapeutics Inc. (NASDAQ:TRIL): Debt to assets
Dec 2020	300822000	21.97M	7.3%
Mar 2021	288288000	15.30M	5.31%
Jun 2021	273684000	14.11M	5.16%
Sep 2021	265360000	22.19M	8.37%

Trillium Therapeutics Inc. (NASDAQ:TRIL): Cash Flow
Dec 2020	-5.19M	11.52M	3.78M
Mar 2021	-17.07M	15.76M	1.63M
Jun 2021	-11.48M	-67.38M	895K
Sep 2021	-13.98M	-62.73M	112K

Trillium Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Trillium Therapeutics
Employees

Trillium Therapeutics Inc. (NASDAQ:TRIL): Employee count
Aug 2023	33
Sep 2023	33
Oct 2023	33
Nov 2023	33
Dec 2023	33
Jan 2024	33
Feb 2024	33
Mar 2024	33
Apr 2024	33
May 2024	33
Jun 2024	33
Jul 2024	33

Trillium Therapeutics
Insider Trading

Trillium Therapeutics Inc. (NASDAQ:TRIL): Insider trades (number of shares)
Period	Buy	Sel
Jan 2021	0	49155
Feb 2021	0	12967
Mar 2021	0	11875
Apr 2021	0	8958
May 2021	0	134146
Jun 2021	0	3646
Jul 2021	0	3646

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	7 Jul 2021	UGER ROBERT officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Shares	3,646	N/A	N/A
Sale	7 Jul 2021	UGER ROBERT officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Shares	3,646	N/A	N/A
Option	7 Jul 2021	UGER ROBERT officer: Chief Scientific Officer officer: Chief Scientific Officer	Stock Option (Right to Buy)	3,646	N/A	N/A
Option	7 Jun 2021	UGER ROBERT officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Shares	3,646	$0.32	$1,148
Sale	7 Jun 2021	UGER ROBERT officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Shares	3,646	$0.32	$1,148
Option	7 Jun 2021	UGER ROBERT officer: Chief Scientific Officer officer: Chief Scientific Officer	Stock Option (Right to Buy)	3,646	$0.32	$1,148
Option	12 May 2021	SKVARKA JAN director, officer: President and CEO director, officer: President an..	Common Shares	23,802	$9.24	$219,883
Sale	12 May 2021	SKVARKA JAN director, officer: President and CEO director, officer: President an..	Common Shares	23,802	$9.24	$219,883
Option	12 May 2021	SKVARKA JAN director, officer: President and CEO director, officer: President an..	Stock Option (Right to Buy)	23,802	$9.24	$219,883
Option	11 May 2021	SKVARKA JAN director, officer: President and CEO director, officer: President an..	Common Shares	106,698	$0.38	$40,545

TRIL insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application CD47 BLOCKADE WITH PARP INHIBITION FOR DISEASE TREATMENT Filling date: 29 Aug 2019 Issue date: 14 Oct 2021	29 Aug 2019	14 Oct 2021
Application	Application CD47 BLOCKADE WITH RADIATION THERAPY Filling date: 5 Nov 2018 Issue date: 12 Aug 2021	5 Nov 2018	12 Aug 2021
Application	Application TREATMENT OF CD47+ DISEASE CELLS WITH SIRP ALPHA-FC FUSIONS Filling date: 23 Dec 2020 Issue date: 8 Jul 2021	23 Dec 2020	8 Jul 2021
Application	Application CD47 BLOCKADE THERAPY WITH CD38 ANTIBODY Filling date: 8 Mar 2019 Issue date: 11 Feb 2021	8 Mar 2019	11 Feb 2021
Application	Application IMPROVEMENTS IN CD47 BLOCKADE THERAPY BY EGFR ANTIBODY Filling date: 8 Mar 2019 Issue date: 11 Feb 2021	8 Mar 2019	11 Feb 2021
Grant	Grant Utility: Treatment of CD47+ disease cells with SIRP.alpha.-Fc fusions Filling date: 25 Apr 2018 Issue date: 2 Feb 2021	25 Apr 2018	2 Feb 2021
Grant	Grant Utility: Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins Filling date: 11 Mar 2019 Issue date: 30 Jun 2020	11 Mar 2019	30 Jun 2020
Application	Application FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS Filling date: 12 Feb 2020 Issue date: 11 Jun 2020	12 Feb 2020	11 Jun 2020
Application	Application CD47 BLOCKADE THERAPY Filling date: 27 Mar 2018 Issue date: 21 May 2020	27 Mar 2018	21 May 2020
Grant	Grant Utility: Fluorinated amide derivatives and their uses as therapeutic agents Filling date: 31 Oct 2016 Issue date: 31 Mar 2020	31 Oct 2016	31 Mar 2020

Trillium Therapeutics
Latest News

Thursday, 3 August 2023
09:22	London capital markets have been surprisingly active in 2023, right?	Proactive Investors
Sunday, 19 March 2023
07:43	MDA Breakout Stocks/ETFs Week 12 - March 2023: High-Frequency Gainers To Give You An Edge	Seeking Alpha
Tuesday, 5 July 2022
10:57	Week 27 MDA Breakout Stocks - July 2022: Short-Term Picks To Give You An Edge	Seeking Alpha
Sunday, 10 April 2022
06:12	Week 15 MDA Breakout Stocks - April 2022: Short-Term Picks To Give You An Edge	Seeking Alpha
Monday, 28 March 2022
06:13	Week 13 MDA Breakout Stocks - April 2022: Short-Term Picks To Give You An Edge	Seeking Alpha
Sunday, 13 March 2022
04:42	Week 11 MDA Breakout Stocks - March 2022: Short-Term Picks To Give You An Edge	Seeking Alpha
Sunday, 6 March 2022
08:26	Week 10 MDA Breakout Stocks - March 2022: Short-Term Picks To Give You An Edge	Seeking Alpha
Sunday, 27 February 2022
07:06	Week 9 MDA Breakout Stocks - March 2022: Short-Term Picks To Give You An Edge	Seeking Alpha
Sunday, 20 February 2022
06:17	Week 8 MDA Breakout Stocks - February 2022: Short-Term Picks To Give You An Edge	Seeking Alpha
Sunday, 13 February 2022
07:36	Week 7 MDA Breakout Stocks - February 2022: Short-Term Picks To Give You An Edge	Seeking Alpha
Sunday, 30 January 2022
07:22	Week 5 MDA Breakout Stocks - February 2022: Short-Term Picks To Give You An Edge	Seeking Alpha
Monday, 24 January 2022
12:36	Week 4 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge	Seeking Alpha
Saturday, 15 January 2022
10:01	Week 3 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge	Seeking Alpha
Sunday, 9 January 2022
09:20	Week 2 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge	Seeking Alpha
Sunday, 2 January 2022
12:35	Week 1 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge	Seeking Alpha
Friday, 24 December 2021
13:51	Week 52 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge	Seeking Alpha
Sunday, 19 December 2021
06:01	Week 51 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge	Seeking Alpha
Sunday, 12 December 2021
06:37	Week 50 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge	Seeking Alpha
Sunday, 5 December 2021
08:53	Week 49 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge	Seeking Alpha
Sunday, 28 November 2021
08:35	Week 48 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge	Seeking Alpha
Wednesday, 15 September 2021
11:28	New Strong Sell Stocks for September 15th	Zacks Investment Research
Saturday, 4 September 2021
08:37	This Is the COVID Vaccine Stock You Want to Own	The Motley Fool
05:55	Why Investors Should Love Pfizer's Acquisition of Trillium	The Motley Fool
Thursday, 26 August 2021
12:14	Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs	Zacks Investment Research
Tuesday, 24 August 2021
13:45	Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion	Zacks Investment Research
13:00	Trillium Therapeutics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Trillium Therapeutics Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – TRIL	Business Wire
12:59	Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News	Zacks Investment Research
Monday, 23 August 2021
21:00	Pfizer To Buy Cancer Biotech Company Trillium For $2.3 Million	The Motley Fool
17:04	What Did the Stock Market Do Today, Aug. 23? 3 Big Stories to Catch Up On.	InvestorPlace
11:06	Trillium Therapeutics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Trillium Therapeutics Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – TRIL	Business Wire

Frequently Asked Questions (FAQ)

What's the price of Trillium Therapeutics stock today?

One share of Trillium Therapeutics stock can currently be purchased for approximately $18.44.
When is Trillium Therapeutics's next earnings date?

Unfortunately, Trillium Therapeutics's (TRIL) next earnings date is currently unknown.
Does Trillium Therapeutics pay dividends?

No, Trillium Therapeutics does not pay dividends.
What is Trillium Therapeutics's stock symbol?

Trillium Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "TRIL".
What is Trillium Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Trillium Therapeutics?

Shares of Trillium Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Trillium Therapeutics have?

As Jul 2024, Trillium Therapeutics employs 33 workers.
When Trillium Therapeutics went public?

Trillium Therapeutics Inc. is publicly traded company for more then 20 years since IPO on 11 Jan 2005.
What is Trillium Therapeutics's official website?

The official website for Trillium Therapeutics is trilliumtherapeutics.com.
Where are Trillium Therapeutics's headquarters?

Trillium Therapeutics is headquartered at 2488 Dunwin Dr, Mississauga, ONTARIO.
How can i contact Trillium Therapeutics?

Trillium Therapeutics's mailing address is 2488 Dunwin Dr, Mississauga, ONTARIO and company can be reached via phone at +1 416 595 0627.

Trillium Therapeutics Inc.

trilliumtherapeutics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.

+1 416 595 0627

2488 Dunwin Dr
Mississauga, ONTARIO 02140

CIK: 0001616212
ISIN: CA89620X5064
CUSIP: 89620X506